Marinus Pharmaceuticals Inc

NASDAQ:MRNS  
14.62
-0.03 (-0.20%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)446.40M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.2 Million
Adjusted EPS-$0.52
See more estimates
10-Day MA$14.58
50-Day MA$13.81
200-Day MA$9.98
See more pivots

MARINUS PHARMACEUTICALS INC Stock, NASDAQ:MRNS

170 N RADNOR CHESTER RD, SUITE 250, RADNOR, PA 19087
United States of America
Phone: 484-801-4670
Number of Employees: 28

Description

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. The company is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of genetic orphan disorders, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. The company is also developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreement with Purdue Neuroscience Company. The company was founded in 2003 and is based in Radnor, Pennsylvania.